ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Allergan Aesthetics (NYSE:ABBV) released data on March 4, 2026 showing Medical Weight Loss (MWL) is reshaping aesthetic demand, with patients prioritizing facial appearance and volume restoration.

Key metrics: 67% changed goals toward appearance, 61% report midface volume loss, 81% of HCPs favor HA fillers, and 60% of GLP-1 users obtain medications from providers who also offer aesthetic services (up from 49%).

Positive

60% of GLP-1 consumers now get medications from providers offering aesthetics (up from 49%)
81% of HCPs identify hyaluronic acid fillers as a top nonsurgical option after GLP-1 weight loss
67% of MWL patients say treatment shifted goals toward improving appearance
One-third of physicians (33%) report increased dermal filler injection volume in their practice

Negative

None.

Key Figures

Patients shifting goals: 67% Benefit from HA fillers: 47% GLP-1 from aesthetic providers: 60% +5 more

8 metrics

Patients shifting goals 67% Patients saying MWL treatment changed goals toward appearance, not just weight

Benefit from HA fillers 47% MWL patients reported by HCPs to benefit most from HA injectable fillers

GLP-1 from aesthetic providers 60% Consumers on GLP-1 medications obtaining them from providers offering aesthetic treatments

Prior GLP-1 figure 49% Consumers on GLP-1 getting them from aesthetic providers in late 2024

Considering aesthetics 40% MWL patients considering professionally administered aesthetic treatment

Midface volume loss 61% GLP-1 patients experiencing midface volume loss

Skin laxity incidence 50% GLP-1 patients with skin laxity

HA fillers as top modality 81% HCPs identifying HA fillers as top nonsurgical modality post GLP-1 weight loss

Market Reality Check

Price: $233.26 Vol: Volume 4,761,682 vs 20-da...

low vol

$233.26 Last Close

Volume Volume 4,761,682 vs 20-day average 7,319,667, indicating lighter-than-normal trading. low

Technical Price 233.26 is trading above 200-day MA at 212.81, reflecting a pre-existing uptrend.

Peers on Argus

Peers show mixed moves: JNJ, AZN, NVS and NVO are up (e.g., NVO +0.80%), while L...

1 Up

Peers show mixed moves: JNJ, AZN, NVS and NVO are up (e.g., NVO +0.80%), while LLY is down (-0.72%). With only one peer in the momentum scanner and no clear directional cluster, trading appears more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Mar 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Phase 3 data	Positive	+0.9%	Positive Phase 3 AFFIRM Crohn’s results for SKYRIZI with strong efficacy data.
Feb 24	Conference appearance	Positive	-0.5%	Announcement of participation in TD Cowen 46th Annual Health Care Conference.
Feb 23	Capacity investment	Positive	+2.1%	Plan to invest $380M in new U.S. API facilities for pipeline support.
Feb 20	FDA approval	Positive	+0.2%	FDA approval of VENCLEXTA plus acalabrutinib regimen for first-line CLL.
Feb 19	Dividend declaration	Positive	-1.9%	Declaration of $1.73 quarterly dividend and highlighting long-term dividend growth.

Pattern Detected

Recent news has been largely positive (clinical data, FDA approval, capacity investment, dividend), with share reactions mostly modest and split between small gains and occasional declines.

Recent Company History

Over the past weeks, AbbVie reported multiple positives: a Phase 3 AFFIRM Crohn’s study with strong remission and endoscopic response data on Mar 02, an FDA approval for a VENCLEXTA plus acalabrutinib CLL regimen on Feb 20, and a planned $380 million API investment in North Chicago announced on Feb 23. A quarterly dividend of $1.73 per share was declared on Feb 19. Market reactions to these constructive updates have been generally modest, with a mix of small gains and pullbacks.

Market Pulse Summary

This announcement underscores growing overlap between medical weight loss and aesthetics, with metri...

Analysis

This announcement underscores growing overlap between medical weight loss and aesthetics, with metrics like 67% of patients shifting goals toward appearance and 60% of GLP-1 users treated by aesthetic providers. For AbbVie, this complements recent clinical and regulatory milestones and its broader obesity-related manufacturing plans. Investors may monitor how demand for hyaluronic acid fillers, GLP-1 usage patterns, and future data releases translate into longer-term franchise strength within aesthetics.

Key Terms

medical weight loss, hyaluronic acid injectable fillers, glp-1 medications, dermal fillers

4 terms

medical weight loss medical

"Medical Weight Loss (MWL) treatments is changing patient behavior, aesthetic priorities"

A medically supervised weight loss program combines clinical assessment, tailored nutrition and exercise plans, behavior counseling, and when appropriate prescription medications or devices to help people lose weight safely. Investors care because these programs turn a common health need into measurable, often recurring revenue streams tied to reimbursement rules, patient retention and regulatory approvals—similar to investing in a managed service that can scale if outcomes and demand are strong.

hyaluronic acid injectable fillers medical

"MWL patients (47%) were reported by HCPs to benefit most from hyaluronic acid injectable fillers"

Hyaluronic acid injectable fillers are gel-like substances injected under the skin to restore lost volume, smooth wrinkles, or reshape features; think of them as tiny cushions that plump and support facial tissue. For investors, they matter because they are a high-margin, often repeat-purchase aesthetic treatment whose sales, safety record, regulatory approvals, and shifting consumer preferences can directly affect revenue, profitability and growth prospects of medical-device and cosmetic companies.

glp-1 medications medical

"60% of consumers receiving GLP-1 medications obtain them from providers who also offer aesthetic treatments"

GLP-1 medications are drugs that copy a natural gut hormone to help the body release insulin, lower blood sugar and reduce appetite by slowing how quickly the stomach empties. For investors, they matter because their strong clinical benefits have driven rapid sales growth, reshaped demand for diabetes and weight-loss treatments, and created regulatory, patent and pricing dynamics that can significantly affect healthcare companies’ revenues and profitability.

dermal fillers medical

"Hyaluronic acid (HA) dermal fillers are a primary treatment option"

Dermal fillers are injectable products placed under the skin to restore lost volume, smooth wrinkles, or enhance facial contours; think of them as temporary internal padding that plumps and reshapes like adding a cushion under a sagging fabric. They matter to investors because demand, pricing, regulatory approvals, safety records, and product longevity directly affect revenue, margin and legal risk for companies in medical aesthetics and pharmaceutical manufacturing.

AI-generated analysis. Not financial advice.

03/04/2026 - 08:00 AM

Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration

67% of patients say MWL treatment changed their goals toward improving appearance, not just weight reductionⁱ.
Nearly half of MWL patients (47%) were reported by HCPs to benefit most from hyaluronic acid injectable fillers when addressing post-weight-loss facial concernsⁱⁱ.
60% of consumers receiving GLP-1 medications obtain them from providers who also offer aesthetic treatments, up from 49% in late 2024ⁱⁱⁱ.

IRVINE, Calif., March 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, shares new data illustrating how the rapid adoption of Medical Weight Loss (MWL) treatments is changing patient behavior, aesthetic priorities, and treatment demand, particularly as facial volume loss emerges as a leading concern.

"Allergan Aesthetics is committed to equipping our customers with data-driven insights, education, and consultation tools to help guide patients safely and effectively through these changes," said Glen Curran, Senior Vice President at Allergan Aesthetics. "We're seeing this new patient population enter aesthetics with different concerns, different goals, and a strong desire for individualized, long-term treatment and care, particularly when it comes to restoring facial balance and volume."

Data Highlights: How GLP-1–Associated Weight Loss Is Changing Aesthetic Care

The data underscores a broader evolution in the aesthetics landscape; patients undergoing medical weight loss are entering aesthetic practices with distinct needs tied to facial volume, structure, and skin quality, many for the first time. As rapid weight loss can accelerate visible changes in the face, early consultation and proactive treatment planning are critical to helping patients understand their options and achieve balanced, natural looking outcomes. For many of these patients, hyaluronic acid fillers can play an important role in addressing volume loss and supporting natural-looking outcomes that align with their overall transformation journey.

Consumer interest in aesthetics is rising with 40% of MWL patients considering a professionally administered aesthetic treatment in a physician's office or medspa^iv. Notably, aesthetic practices are increasingly serving as an entry point into the category; 60% of consumers using GLP-1 medications now receive them from healthcare providers who also offer aesthetic treatments, up from roughly half just one year ago^v.

According to Allergan Aesthetics studies and consumer market research, physicians report that MWL is driving meaningful shifts in facial concerns, treatment preferences, and patient demand:

Facial volume loss is the leading aesthetic impact, with 61% of GLP-1 patients experiencing midface volume loss, followed by skin laxity (50%), and facial wrinkles/folds (35%)^vi.
Hyaluronic acid (HA) dermal fillers are a primary treatment option, with 81% of HCPs identifying HA fillers as a top nonsurgical modality following GLP-1 related weight loss^vii.
One-third of physicians (33%) say GLP-1 usage has increased the overall volume of dermal filler injections in their practice^viii.

Allergan Aesthetics has been studying the intersection of MWL and aesthetic medicine since early 2022. Allergan Aesthetic consumer market research closely mirrors data the company presented at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting and was published in January 2026 in the Aesthetic Surgery Journal's Open Forum, "Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations," demonstrating that patients are increasingly seeking physician-guided aesthetic solutions to address changes in facial appearance following weight loss.

"As a dermatologist, I've seen firsthand how medical weight loss can significantly impact the face," said Dr. Joely Kaufman, a board-certified dermatologist in Miami, FL. "This data reflects what we're seeing in practice – patients who are excited about their weight loss success are looking for personalized, medically appropriate solutions that restore balance and confidence."

Through proprietary consumer research, physician collaboration, and data shared at leading medical forums, the company continues to translate emerging trends into actionable insights for healthcare providers.

Download our MWL & Aesthetics infographic to learn more.

Media Contact

Kate McShane
Director, Corporate Communications
Cell +1862.325.6984
Email Kate.McShane@allergan.com

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

*An AbbVie company



ⁱ Allergan Aesthetics, July 2024, GLP-1 Consumer Study
ⁱⁱ Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss, Allergan Aesthetics and AbbVie, American Society for Dermatologic Surgery 2025, Chicago, IL
ⁱⁱⁱ Allergan Aesthetics 2025 Consumer Aesthetic Tracker – Key Findings for Q3 2025: Quantitative Research with Consumers
^iv Allergan Aesthetics Weight Loss Treatment: Patient Interest and Types of Treatments, June 2025 Assessment
^v Allergan Aesthetics 2025 Consumer Aesthetic Tracker – Key Findings for Q3 2025: Quantitative Research with Consumers
^viSurvey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss, Allergan Aesthetics and AbbVie, American Society for Dermatologic Surgery 2025, Chicago, IL
^vii Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss, Allergan Aesthetics and AbbVie, American Society for Dermatologic Surgery 2025, Chicago, IL
^viii Allergan Aesthetics Weight Loss Treatment: Patient Interest and Types of Treatments, June 2025 Assessment

View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-highlights-medical-weight-loss-mwl-data-and-the-changing-profile-of-patients-302703256.html

SOURCE AbbVie

FAQ

How is MWL changing patient priorities for Allergan Aesthetics (ABBV) as of March 4, 2026?

Patients are prioritizing facial appearance and volume restoration after MWL, shifting goals beyond weight loss. According to the company, 67% of MWL patients reported their treatment changed goals toward improving appearance rather than only reducing weight, driving demand for facial procedures.

What proportion of GLP-1 patients experience midface volume loss, and what does ABBV recommend?

61% of GLP-1 patients reported midface volume loss after weight loss. According to the company, early consultation and hyaluronic acid fillers are highlighted as key nonsurgical options to restore facial balance and natural-looking outcomes.

Has GLP-1 adoption affected where patients receive care, according to Allergan Aesthetics (ABBV)?

Yes — 60% of consumers receiving GLP-1s now obtain them from providers who also offer aesthetic treatments. According to the company, this is up from 49% in late 2024, indicating aesthetic practices are increasingly an entry point for MWL patients.

How prevalent are HCP endorsements of HA dermal fillers for post-GLP-1 aesthetic care (ABBV data)?

HCPs widely favor HA fillers, with 81% identifying them as a top nonsurgical modality post-GLP-1 weight loss. According to the company, HA fillers are viewed as a primary treatment to address volume loss and support natural outcomes.

What operational impact has GLP-1 usage had on aesthetic practices, per Allergan Aesthetics (ABBV)?

One-third of physicians (33%) report GLP-1 usage increased overall dermal filler injection volume in their practice. According to the company, this trend is changing treatment demand and prompting providers to adapt consultation and care pathways.

ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS